Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.

This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.

India, March 21 -- Students from the Department of Biotechnology, Chandigarh College of Technology (CCT), Chandigarh Group of Colleges, Landran, demonstrated outstanding performance at the Tech ...

Researchers at Kenya’s Ol Pejeta Conservancy witnessed a biological breakthrough recently when a southern white rhinoceros ...

Mayo Clinic in Arizona has two campuses. The largest is in north Phoenix, where a big expansion is underway. Here's what to ...

The hefty funding will support a U.S. and China-based startup that’s amassed a pipeline of nearly 20 drugs and formed two lucrative partnerships with Sanofi.

Novartis (NOVN) announces acquisition of experimental breast cancer drug SNV4818 for up to $3B. Stock dipped 0.94% on the news. Deal closes H1 2026.

This week on "The Readout LOUD," a conversation with biotech "godfather" Stelios Papadapolous live from #STATBreakthrough.

The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to ...

AAA Biotech’s Validated Antibodies, Recombinant Proteins, and ELISA Kits Power Breakthrough Research Across Drug ...

Researchers use a novel process involving engineered Escherichia coli to turn plastic waste into levodopa, a frontline ...

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the Company will ...